Supaglutide
Sources
registry, as of 2021-09-17Stale
https://clinicaltrials.gov/study/NCT03745885
A Study of the Efficacy and Safety of Supaglutide in Healthy Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 48. Conditions Diabetes Mellitus, Type 2. This study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug Supaglutide proposed dosing once (or twice) weekly in Chinese healthy subjects.
ClinicalTrials.gov NCT03745885 protocol and results modules
registry, as of 2024-12-06Stale
https://clinicaltrials.gov/study/NCT04998032
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 620. Conditions Type2 Diabetes. This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after metformin treatment. This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III ). The p
ClinicalTrials.gov NCT04998032 protocol and results modules
registry, as of 2024-08-07Stale
https://clinicaltrials.gov/study/NCT04994288
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1). Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 547. Conditions Type2 Diabetes. This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention. This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase I
ClinicalTrials.gov NCT04994288 protocol and results modules
registry, as of 2021-09-17Stale
https://clinicaltrials.gov/study/NCT04314622
A Study of Supaglutide in Chinese Type 2 Diabetes Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Enrollment 40. Conditions Diabetes Mellitus, Type 2. A study on the safety, efficacy, pharmacokinetics and pharmacodynamics of Supaglutide dosing weekly and bi-weekly in patients with type 2 diabetes mellitus.
ClinicalTrials.gov NCT04314622 protocol and results modules
registry, as of 2024-09-20Stale
https://clinicaltrials.gov/study/NCT06605287
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients. Overall status UNKNOWN. Phases not stated. Lead sponsor Nanjing First Hospital, Nanjing Medical University. Enrollment 100. Conditions Type 2 Diabetes Mellitus. Glucagon like peptide-1 receptor agonist (GLP-1RA) can enhance insulin secretion and inhibit glucagon secretion in a glucose concentration dependent manner, delay gastric emptying, and reduce food intake through central appetite inhibition, thus achieving the effect of lowering g
ClinicalTrials.gov NCT06605287 protocol and results modules
publication, as of 2026-10-13Stale
https://pubmed.ncbi.nlm.nih.gov/42870102/
Efsubaglutide Alfa: A Comprehensive Pharmacological Review. Efsubaglutide alfa (also known as supaglutide) is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) engineered as a GLP-1 analogue fused to a human immunoglobulin G2 (IgG2) fragment crystallisable (Fc) domain. This narrative review summarises published and publicly ava
PMID 42870102